Clinical Trial Details
— Status: Active, not recruiting
Administrative data
| NCT number |
NCT05278299 |
| Other study ID # |
UW 21-664 |
| Secondary ID |
|
| Status |
Active, not recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
October 1, 2021 |
| Est. completion date |
September 30, 2023 |
Study information
| Verified date |
March 2022 |
| Source |
The University of Hong Kong |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Glaucoma remains a leading cause for irreversible visual impairment and blindness worldwide
and it disproportionately affects people residing in Asia, there is a need to ensure optimal
management of the disease in patients with glaucoma. The ability to estimate the rates of
structural and functional loss in patients with glaucoma will enable clinicians to identify
those with rapidly deteriorating conditions or those at-risk, and to therefore provide timely
treatment to these patients. Despite this, there are currently several challenges in
identifying rapid-progressors in glaucoma, including lack of consensus on the definition of
'rapid' progression and what rates of change of visual field (VF) encompass clinically
significant deterioration relevant to the patients. As such, the Asia Glaucoma Registry is
intended to collect data to advance the understanding of glaucoma and its progression in Asia
and to understand the management patterns of glaucoma in Asia. The Registry will also provide
research data for future collaborative scientific research projects.
Description:
Glaucoma remains a leading cause for irreversible visual impairment and blindness worldwide
and it disproportionately affects people residing in Asia [Tham et al, 2014]. It is well
established that the epidemiology and natural history of glaucoma in patients in the Asia
region is different from its western counterparts. Compared with the other parts of the
world, the prevalence of primary angle closure glaucoma (PACG) was highest in Asia [Tham et
al, 2014]. The prevalence of PACG was higher in East Asia than South East Asia, while the
burden of primary open angle glaucoma (POAG) was projected to be the highest in South-Central
Asia by 2040 [Chan et al, 2016]; this suggests that ethnic differences within Asia may be a
contributing factor to the differences in the prevalence of different types of glaucoma.
Furthermore, studies have suggested the prevalence of normal pressure glaucoma is also higher
in Asians than Caucasians [ Chen et al , 2020 ] Given the disproportionate burden of glaucoma
in Asia, there is a need to ensure optimal management of the disease in patients with
glaucoma. The ability to estimate the rates of structural and functional loss in patients
with glaucoma will enable clinicians to identify those with rapidly deteriorating conditions
or those at-risk, and to therefore provide timely treatment to these patients.
Despite this, there are currently several challenges in identifying rapid-progressors in
glaucoma, including lack of consensus on the definition of 'rapid' progression and what rates
of change of visual field (VF) encompass clinically significant deterioration relevant to the
patients. As such, the Asia Glaucoma Registry is intended to collect data to advance the
understanding of glaucoma and its progression in Asia and to understand the management
patterns of glaucoma in Asia. The Registry will also provide research data for future
collaborative scientific research projects. Glaucoma remains a leading cause for irreversible
visual impairment and blindness worldwide and it disproportionately affects people residing
in Asia [Tham et al, 2014]. It is well established that the epidemiology and natural history
of glaucoma in patients in the Asia region is different from its western counterparts.
Compared with the other parts of the world, the prevalence of primary angle closure glaucoma
(PACG) was highest in Asia [Tham et al, 2014]. The prevalence of PACG was higher in East Asia
than South East Asia, while the burden of primary open angle glaucoma (POAG) was projected to
be the highest in South-Central Asia by 2040 [Chan et al, 2016]; this suggests that ethnic
differences within Asia may be a contributing factor to the differences in the prevalence of
different types of glaucoma. Furthermore, studies have suggested the prevalence of normal
pressure glaucoma is also higher in Asians than Caucasians [ Chen et al , 2020 ] Given the
disproportionate burden of glaucoma in Asia, there is a need to ensure optimal management of
the disease in patients with glaucoma. The ability to estimate the rates of structural and
functional loss in patients with glaucoma will enable clinicians to identify those with
rapidly deteriorating conditions or those at-risk, and to therefore provide timely treatment
to these patients.
Despite this, there are currently several challenges in identifying rapid-progressors in
glaucoma, including lack of consensus on the definition of 'rapid' progression and what rates
of change of visual field (VF) encompass clinically significant deterioration relevant to the
patients. As such, the Asia Glaucoma Registry is intended to collect data to advance the
understanding of glaucoma and its progression in Asia and to understand the management
patterns of glaucoma in Asia. The Registry will also provide research data for future
collaborative scientific research projects.
References:
Chan EW, et al. Glaucoma in Asia: regional prevalence variations and future projections. Br J
Opthalmol 2016;100(1):78-85.
Chen MJ. Normal tension glaucoma in Asia : Epidemiology, pathogenesis, diagnosis, and
management. Taiwan J Ophthalmo ;10 250-4. He M, et al. Angle-closure glaucoma in East Asian
and European people. Different diseases? Eye (Lond) 2006;20(1):3-12.
Tham Y, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040:
a systematic review and metaanalysis. Ophthalmology 2014;121(11):2081-90.
Yip JLY, Foster PJ. Ethnic differences in primary angle-closure glaucoma. Curr Opin
Ophthalmol 2006;17(2):175-80.
